Q2 EPS Estimate for Prelude Therapeutics Lifted by Analyst

Prelude Therapeutics Incorporated (NASDAQ:PRLD) – Research analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for Prelude Therapeutics in a report released on Wednesday, July 15th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.17) per share for the quarter, up from their previous estimate of ($0.23). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Prelude Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Prelude Therapeutics’ Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.62) EPS.

Other analysts also recently issued research reports about the stock. Weiss Ratings raised shares of Prelude Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Zacks Research upgraded Prelude Therapeutics to a “hold” rating in a research report on Tuesday, April 28th. Finally, D. Boral Capital initiated coverage on Prelude Therapeutics in a report on Monday, May 4th. They set a “buy” rating and a $9.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.67.

Prelude Therapeutics Price Performance

PRLD stock opened at $4.18 on Friday. The stock has a market cap of $332.90 million, a price-to-earnings ratio of -4.18 and a beta of 0.95. The company has a 50 day simple moving average of $4.39 and a 200 day simple moving average of $3.56. Prelude Therapeutics has a 1 year low of $0.75 and a 1 year high of $5.69.

Prelude Therapeutics (NASDAQ:PRLD) last issued its earnings results on Tuesday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.14. The firm had revenue of $4.58 million during the quarter, compared to the consensus estimate of $4.58 million.

Insider Activity at Prelude Therapeutics

In other news, Director Orbimed Advisors Llc purchased 2,815,315 shares of the stock in a transaction dated Tuesday, April 21st. The shares were acquired at an average cost of $4.44 per share, for a total transaction of $12,499,998.60. Following the acquisition, the director owned 11,808,945 shares of the company’s stock, valued at approximately $52,431,715.80. This represents a 31.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David P. Bonita purchased 2,815,315 shares of Prelude Therapeutics stock in a transaction on Tuesday, April 21st. The shares were acquired at an average cost of $4.44 per share, with a total value of $12,499,998.60. Following the completion of the transaction, the director directly owned 11,808,945 shares in the company, valued at $52,431,715.80. The trade was a 31.30% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 49.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PRLD. AQR Capital Management LLC lifted its stake in shares of Prelude Therapeutics by 170.7% in the 1st quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after purchasing an additional 21,330 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Prelude Therapeutics in the 2nd quarter valued at about $34,000. XTX Topco Ltd increased its position in Prelude Therapeutics by 72.4% in the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after acquiring an additional 17,873 shares during the period. Shay Capital LLC acquired a new position in shares of Prelude Therapeutics during the second quarter worth about $61,000. Finally, Jane Street Group LLC purchased a new stake in shares of Prelude Therapeutics during the 2nd quarter worth $74,000. 79.72% of the stock is owned by hedge funds and other institutional investors.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.